<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058274</url>
  </required_header>
  <id_info>
    <org_study_id>HIPER-AT-TORBI</org_study_id>
    <nct_id>NCT05058274</nct_id>
  </id_info>
  <brief_title>Clinical Results of a Monofocal Aspheric Bitoric Intraocular Lens With Plate Haptics in Hyperopic Eyes (HIPER-AT-TORBI)</brief_title>
  <acronym>HIPER-AT-TORBI</acronym>
  <official_title>Clinical Results of a Monofocal Aspheric Bitoric Intraocular Lens With Plate Haptics in Hyperopic Eyes (HIPER-AT-TORBI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OFTALVIST (Oftalmología Vistahermosa S.L)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OFTALVIST (Oftalmología Vistahermosa S.L)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational post-marketing study with prospective follow-up of CE marked medical devices&#xD;
      aimed at the treatment of hyperopia and astigmatism in patients with cataract. The objective&#xD;
      is to evaluate the clinical results of the implantation of the monofocal aspheric bitoric&#xD;
      intraocular lens (IOL) with AT-TORBI 709 plate haptics in cataract surgery of hyperopic eyes&#xD;
      with astigmatism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients participating in the study will have the intraocular lens (IOL) AT TORBI 709&#xD;
      implanted from Carl Zeiss Meditec AG, Jena, Germany, with CE marking. All patients will be&#xD;
      treated according to standard clinical practice. A preoperative and postoperative evaluation&#xD;
      will be carried out one month, six and twelve months after the intervention where the&#xD;
      following tests will be performed: refraction, corneal topography, measurement of visual&#xD;
      acuity with and without correction, slit lamp examination, eye biometry using the IOLMaster&#xD;
      700 Carl Zeiss Meditec AG, Jena, Germany, CE marked optical non-contact biometer, contrast&#xD;
      sensitivity with the CC-100 screen (Topcon Europe, The Netherlands), and the Catquest-9SF&#xD;
      (European Registry of Quality Outcomes for Cataract and Refractive Surgery, founded by the&#xD;
      European Society of Cataract and Refractive Surgeons). The sponsor has received an&#xD;
      unrestricted research grant by Zeiss.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the refractive error</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of the refractive error (equivalent spherical error, the refractive cylinder and the astigmatism vectors (J0 and J45) )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the rotational stability</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of the rotational stability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of corneal topography</measure>
    <time_frame>12 months</time_frame>
    <description>Measure of corneal topography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of ocular biometry</measure>
    <time_frame>12 months</time_frame>
    <description>Measure of ocular biometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of contrast sensitivity</measure>
    <time_frame>12 months</time_frame>
    <description>Measure of contrast sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction questionaire</measure>
    <time_frame>12 months</time_frame>
    <description>For several questions percentage of respondants answering each of five possible provided answers ranging progressively from strong disatisfaction to strong satisfaction (1-4) as well as an answer for those patients who cannot decide (5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit lamp examination</measure>
    <time_frame>12 months</time_frame>
    <description>Slit lamp examination</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Astigmatism</condition>
  <condition>Far Sightedness</condition>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <description>All participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implant of the AT-TORBI 709 lens</intervention_name>
    <description>Implant of the AT-TORBI 709 lens</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are going to undergo conventional cataract surgery by phacoemulsification&#xD;
        following regular clinical practice and present hyperopia with astigmatism.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of 50 years of age or older to undergo cataract surgery with&#xD;
             phacoemulsification&#xD;
&#xD;
          2. Patient who signs the informed consent.&#xD;
&#xD;
          3. Regular corneal astigmatism between 1.0D and 4.0D.&#xD;
&#xD;
          4. IOL power between 21D and 26D&#xD;
&#xD;
          5. Target-target distance measured with the IOLMaster 700 biometer (Carl Zeiss Meditec&#xD;
             AG) greater than 11.6 mm.&#xD;
&#xD;
          6. Patients with hyperopia between 1.0D and 4.0D.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who do not provide informed consent&#xD;
&#xD;
          2. Patients who do not understand the study procedure&#xD;
&#xD;
          3. Previous corneal surgery.&#xD;
&#xD;
          4. Irregular cornea (eg keratoconus)&#xD;
&#xD;
          5. myopic patients&#xD;
&#xD;
          6. Eye abnormalities or pathologies that could reduce the visual function or stability of&#xD;
             the IOL (eg severe amblyopia or macular degeneration)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Tañá Rivero, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>OFTALVIST (Oftalmología Vistahermosa S.L)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María Cobo</last_name>
    <phone>+34901010190</phone>
    <email>maria.cobo@oftalvist.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>OFTALVIST (Oftalmología Vistahermosa S.L.)</name>
      <address>
        <city>Alicante</city>
        <zip>03015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cobo</last_name>
      <phone>+34963513304</phone>
      <email>maria.cobo@oftalvist.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFTALVIST (Oftalmología Vistahermosa S.L.)</name>
      <address>
        <city>Valencia</city>
        <zip>46004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Cobo</last_name>
      <phone>+34901010190</phone>
      <email>maria.cobo@oftalvist.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>A publication summarizing the results of the study will be made public after the study termination.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

